Regeneron Pharmaceuticals Inc. buy kasimir
Start price
29.09.15
/
50%
€415.02
Target price
02.02.16
€541.20
Performance (%)
-12.41%
End price
02.02.16
€363.52
Summary
This prediction ended on 02.02.16 with a price of €363.52. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -12.41%. kasimir has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.000% | 0.000% | 21.054% | -16.677% |
| iShares Core DAX® | 1.498% | -0.265% | 5.212% | 52.591% |
| iShares Nasdaq 100 | 1.854% | -0.066% | 37.788% | 90.508% |
| iShares Nikkei 225® | 0.411% | 4.084% | 60.701% | 76.928% |
| iShares S&P 500 | 1.479% | 0.783% | 26.350% | 66.805% |
Comments by kasimir for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Schnäppchenpreis bei Regeneron
Langfristiger Kauf von REGN um die 465$, Ziel 10-20% in 6 Monaten.
(Stop Loss Kurs erreicht)